Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Cerilliant
Mallinckrodt
Moodys
Healthtrust
Medtronic
Teva
Deloitte
Accenture

Generated: June 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,119,876

« Back to Dashboard

Which drugs does patent 9,119,876 protect, and when does it expire?

Patent 9,119,876 protects ADRENALIN and is included in two NDAs.

This patent has five patent family members in five countries.
Summary for Patent: 9,119,876
Title:Epinephrine formulations
Abstract: Pharmaceutical compositions comprising epinephrine, methods of administration, and methods of making the same. Compositions may comprise at least one of an active agent, a pH raising agent, an antioxidant, a transition metal complexing agent, a pH lowering agent, a tonicity regulating agent, optionally a preservative, and optionally a solvent.
Inventor(s): Kannan; Vinayagam (Rochester, MI), Irish; Patrick (Sterling Heights, MI), Bergren; Michael (Henderson, NV)
Assignee: PAR PHARMACEUTICAL, INC. (Woodcliff Lake, NJ)
Application Number:14/657,990
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,119,876
Patent Claim Types:
see list of patent claims
Composition;

Drugs Protected by US Patent 9,119,876

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Par Sterile Products ADRENALIN epinephrine SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS 204200-001 Dec 7, 2012 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Par Sterile Products ADRENALIN epinephrine SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS 204640-001 Dec 18, 2013 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,119,876

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,295,657 Epinephrine formulations ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 9,119,876

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2016233682 ➤ Try a Free Trial
Canada 2978464 ➤ Try a Free Trial
China 107614017 ➤ Try a Free Trial
European Patent Office 3268045 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Merck
Colorcon
Cipla
Cerilliant
McKinsey
Deloitte
Julphar
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.